** Shares of Orthocell Ltd rise as much as 10.4% to A$0.53, their highest since Dec 17, 2021
** Biotechnology firm says it has received a regulatory approval from the Health Sciences Authority in Singapore
** Co says approval is for OCC to commence sales of its nerve repair product, Remplir, in Singapore
** Adds, it is on track to receive U.S. FDA regulatory clearance in Q1 CY25
** OCC stock up 17.1% YTD
(Reporting by Ayushman Ojha in Bengaluru)
((Ayushman.ojha@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。